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Objective—Clinical studies have demonstrated that hyperglycaemia represents a major risk factor in the development of
the endothelial impairment in diabetes, which is the first step in vascular dysfunction. Using non-obese diabetic mice,
we have evaluated the role of the adrenergic system and eNOS on progression of the disease
Methods and Results—When glycosuria is high (20 to 500 mg/dL), there is a selective reduction in the response to 1 and
2 agonists but not to dopamine or serotonin. When glycosuria is severe (500 to 1000 mg/dL), there is a complete
ablation of the contracture response to the 1 receptor agonist stimulation and a marked reduced response to 2 agonist
stimulation. This effect is coupled with a reduced expression of 1 and 2 receptors, which is caused by an inhibition
at transcriptional level as demonstrated by RT-PCR. In the severe glycosuria (500 to 1000 mg/dL), although eNOS
expression is unchanged, caveolin-1 expression is significantly enhanced, indicating that high glucose plasma levels
cause an upregulation of the eNOS endogenous inhibitory tone. These latter results correlate with functional data
showing that in severe glycosuria, there is a significant reduction in acetylcholine-induced vasodilatation.
Conclusions—Our results show that in diabetes development, there is a progressive selective downregulation of the 1 and
2 receptors. At the same time, there is an increased expression of caveolin-1, the endogenous eNOS inhibitory protein.
Thus, caveolin-1 could represent a new possible therapeutic target in vascular impairment associated with diabetes.
(Arterioscler Thromb Vasc Biol. 2004;24:721-726.)
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It is well established that the appearance of cardiovasculardisorders is much more frequent and severe in diabetic than
in healthy subjects.1,2 Clinical studies have shown that hy-
perglycaemia represents a major risk factor in the develop-
ment of the endothelial impairment, which is the first step in
vascular dysfunction.3–7 Up to 80% of deaths in patients with
diabetes are closely associated with vascular diseases,8 in-
cluding coronary atherosclerosis, macroangiopathy, auto-
nomic neuropathy, and diabetic cardiomyopathy.9,10
Type 1 diabetes, or insulin-dependent diabetes mellitus
(IDDM), is an autoimmune disease characterized by a islet
inflammation or insulitis, followed by progressive destruction
of pancreatic  cells, followed by insulin secretion deficiency
resulting in hyperglycaemia.11,12 The majority of current
knowledge on the mechanisms involved in the
hyperglycaemia-induced endothelial dysfunction has been
obtained from vessels harvested from streptozocin-induced or
alloxan-induced diabetic rabbits,13,14 rats,15–17 and mice.18,19 It
has to be considered that these widely used animal models
rely on a rapid and extensive Langerhans islet  cell damage,
characterized by the onset of high-level glycemia. This rapid
shift from normal to high glycemia levels represents a critical
limitation for these experimental models of IDDM because
the appearance of hyperglycemia is not gradual as it is in
humans. An alternative experimental approach is represented
by non-obese diabetic mice (NOD/Ltj), a strain that sponta-
neously has autoimmune diabetes development with remark-
able analogy to human IDDM.20,21 The disease is character-
ized by lymphocyte infiltration into the pancreatic islets,
which progressively induces pancreatic  cell necrosis lead-
ing to IDDM.22 Diabetes develops gradually in mice and its
onset is week 15. Thus, this mouse strain represents an
elective tool in investigating the vascular complications
linked to diabetes development, because it is possible to
follow-up the disease from its onset as well as during its
progression. The relation between the disease progression and
the onset of the vascular impairment has never been investi-
gated in details. By using NOD mice, we have investigated on
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the role of sympathetic system by using aortas isolated from
mice with different levels of glycosuria. In addition, we have
also evaluated the involvement of eNOS and of its endoge-
nous regulatory protein, caveolin-1 (CAV-1).
Methods
Phenilephrine-Induced Vasoconstriction Is
Reduced in NOD Aortic Rings and Is Closely
Related to Glycosuria
To investigate whether diabetes causes changes in vascular reactiv-
ity, phenilephrine (PE)-induced cumulative concentration–response
curve was performed in control and NOD mice that were divided in
3 groups according to glycosuria/glycemia levels (Figure 1). Because
NOD group 1 mice demonstrated a similar pattern of response as did
CD-1 mice, indicating that at this stage of the disease no pathological
changes occurred, CD-1 and NOD group 1 mice have been consid-
ered as normal control response. In NOD groups 2 and 3, the
PE-induced cumulative concentration–response curve was signifi-
cantly reduced when compared with NOD group 1 and CD-1 mouse
aortic rings (Figure 2A). In particular, PE-induced contractions in
NOD group 2 were significantly reduced compared with NOD group
1 and CD-1 mouse aortic rings. In addition, NOD group 3 PE-
induced contractions were abolished. Conversely, 5-HT-induced
(Figure I, available online at http://atvb.ahajournals.org; 5-HT [A]
and DA [B] on aortic rings harvested from NOD mice. 5-HT–
induced and DA-induced cumulative concentration–response curves
[10 nM to 30 mol/L] were not significantly different in NODs and
CD-1 mice. SNP-induced [C] cumulative concentration–response
curves showed no significant difference between NOD groups 1, 3,
and CD-1 mice. Data are presented as meanSEM of percent of
vasorelaxation, n8 for each group) and DA-induced cumulative
concentration–response curves were not significantly different be-
tween aortic rings from all NOD mouse groups and were similar to
CD-1 mouse aortic rings. These observations showed that with
diabetes progression, as assessed by glycosuria, NOD mice have a
selective deficit to 1 adrenergic stimulation.
Isop-Induced Vasorelaxation Is Reduced in NOD
Aortic Rings and Is Closely Related to Glycosuria
Isop-induced cumulative–concentration response curve was per-
formed to investigate whether the reduced response of 1 adrenergic
receptors was shared with 2 adrenergic receptors. As shown in
Figure 2C, Isop-induced cumulative concentration–response curve
was significantly reduced compared with NOD group 1 and CD-1
mice aortic rings. In particular, Isop-induced vasorelaxation in NOD
group 2 results were significantly curtailed when compared with
NOD group 1 and CD-1 mice aortic rings. Again, in NOD group 3,
there was a major effect and Isop-induced vasorelaxation was
markedly reduced. Thus, with diabetes progression, NOD mice
appear to be less responsive to 2 adrenergic stimulation.
RT-PCR and Western Blot Studies
The effects observed in the functional experiments suggested hypo-
functionality of 1 and 2 adrenergic receptors or a reduction in
number of the adrenergic receptors. To further verify this hypothesis,
we performed a Western blot analysis on NOD groups 1, 2, 3, and
CD-1 aortas for 1 adrenergic receptor. As shown in Figure 3, 1
(Figure 3A) and 2 (Figure 3B) receptor expression was reduced.
This reduction was related to diabetes progression, with a remarkable
reduction of receptor expression in NOD group 3 compared with
NOD group 1 and CD-1 aortas (Figure 3A and 3B). These results
reinforce the finding that with diabetes progression, an impairment
of adrenergic function occurs in 1-mediated vasoconstriction and
2-mediated vasorelaxation caused by a reduction of receptor ex-
pression. This view was further confirmed by the RT-PCR experi-
ment (Figure 3C). PCR analysis demonstrated a significantly de-
creased 1 and 2 mRNA expression in NOD 3 aortas in comparison
with NOD 1 mice, indicating that the reduction of receptor expres-
sion was caused by an inhibition of their transcription.
Results
Ach-Induced, but not SNP-Induced Vasorelaxation
Is Reduced in NOD Aortic Rings
Ach causes an endothelium nitric oxide (NO)-dependent
relaxation. In NOD group 3, the Ach-induced cumulative
concentration response curve was significantly reduced com-
pared with NOD groups 1, 2, and CD-1 mouse aortic rings
(Figure 2D). Because PE-induced contraction in NOD groups
2 and 3, mouse aortic rings were weaker (see previous) when
compared with CD-1 mice. Ach cumulative concentration–
response curve was performed on 5-HT precontracted rings
(Figure 2D). To verify the integrity of smooth muscle,
SNP-induced vasorelaxation (NO donor) was also investi-
gated. SNP-induced cumulative concentration–response
curves showed no significant difference among aortic rings
from all NOD groups and CD-1 mice (Figure I), indicating
that diabetes does not directly influence smooth muscle
relaxation mediated by NO. To define the involvement of
basal NO release in Ach-induced vasorelaxation, the tonic
tone was removed by using a NO inhibitor. Increase in
tension development generated by the NO synthase inhibitor
L-NAME (100 mol/L) on 5-HT precontracted rings obtained
from NOD groups 2 and 3 mice was significantly reduced
compared with NOD group 1 and CD-1 mice (Figure 2B).
This effect is more consistent in NOD group 3 aortic rings,
suggesting that severe diabetic conditions result in an impair-
ment of basal NO release.
Figure 1. Correspondence between the NOD mice age and
value of glycemia or glycosuria. Glycemia (A) and glycosuria (B)
are elevated in an age-dependent fashion. The continuous line
(A) indicates average glucose blood value in normoglycemic
mice. The content of glucose in urine and plasma was mea-
sured by using calorimetric reaction. **P0.01, ***P0.001 ver-
sus NOD I; ##P0.01, ###P0.001 versus NOD II. Data are
presented as meanSEM, n12 for each group.
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Basal Release of NO, eNOS, and Caveolin-1
Involvement in NOD Aortic Rings
To investigate if the reduction of Ach-induced vasorelaxation
was related to a reduction in eNOS expression, we performed
Western blot analysis of eNOS expression on NOD groups 1,
2, 3, and CD-1 aortas. As shown in Figure 4A, there was no
difference of eNOS expression in the NOD group 3 compared
with the NOD groups 1, 2, and CD-1 aortas, whereas
caveolin-1 expression was significantly enhanced in NOD
group 3 mice (Figure 4B and 4C). This result suggests that the
impairment of Ach-induced vasorelaxation in NODs is not
caused by a reduced eNOS expression but by an enhanced
negative modulation of eNOS by caveolin-1.
Cell Experiments with Normal and High
Glucose Environment
To test the effect of high glucose on eNOS activity (eg, NO
production), we used 2 cell lines, BAEC and HEK293, stable
Figure 2. A, PE-induced cumulative concentration–response curve (10
nM to 30 mol/L) was reduced in NOD group 2 (***P0.001) com-
pared with NOD group 1 and CD-1 mice. In NOD group 3,
PE-induced vasoconstriction is virtually absent (***P0.001 versus
NOD group 1 and CD-1 mice; ###P0.001 versus NOD group 2).
Effects of L-NAME–induced (B) increases in isometric tension were
progressively reduced in NOD groups 2 (*P0.05) and 3 (**P0.01,
#P0.05 versus NOD group 2) compared with NOD group 1 and
CD-1 mice. Data are presented as meanSE of the increase of ten-
sion, n6 for each group. C, Isop-induced cumulative concentration–
response curve (10 nM to 30 mol/L) was progressively reduced in
NOD groups 2 and 3 compared with NOD group 1 and CD-1 mice.
Isop-induced vasorelaxation in NOD group 2 was significantly dimin-
ished when compared with NOD group 1 and CD-1 mice
(***P0.001). Reduced vasorelaxation was even more pronounced in
NOD group 3 mice (***P0.001 versus NOD group 1 and CD-1 mice;
##P0.01 versus NOD group 2). Data are presented as meanSEM
of the increase of tension, n8 for each group. D, Ach-induced
cumulative concentration–response curve was significantly reduced in
NOD group 3 compared with NOD groups 1, 2, and CD-1 mice
(***P0.001). In this protocol, aortic rings were precontracted with
5-HT because PE-induced contraction was weaker (see Figure 2) in
NOD groups 2 and 3 compared with NOD group 1 and CD-1 mice.
Figure 3. A, Densitometric analysis shows that there is a remark-
able reduction of 1 adrenergic receptor expression in NOD groups
2 and 3 compared with NOD group 1 and CD-1 aortas. The blot
shown is representative of 3 separate experiments. **P0.01;
***P0.001 versus CD-1 and NOD-1. B, Western blot analysis on
NOD groups 1, 2, 3 and CD-1 aortas for 2 adrenergic receptor.
Densitometric analysis shows that there is a remarkable reduction
of 2 adrenergic receptor expression in NOD group 3 compared
with NOD group 1 and CD-1 aortas. The blot shown is representa-
tive of 3 separate experiments. **P0.01, ***P0.001 versus CD-1
and NOD 1. C, mRNA expression of 1 and 2 receptors is
reduced in NOD 3 mouse aorta. M indicates molecular masses; ,
negative control (water); , positive control; 1, NOD 1 mouse
aorta; 2, NOD 2 mouse aorta. The RT-PCR shown is representative
of 3 separate experiments.
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transfected with eNOS.24 BAEC in normal glucose environment
produces a basal release of NO of2 nM of nitrite, whereas on
stimulation with calcium ionophore A-23187 nitrite levels shift
to13 nM with a 6-fold increase in the response. When cells are
cultured in high glucose levels, the basal level of NO release was
not significantly affected whereas the stimulated release by
A-21387 was significantly reduced by 50% (Figure 5A). This
reduced NO release correlates with the increase in caveolin-1
expression in BAEC (Figure 5B). In the same experimental
setting, NOS activity was determined by monitoring conversion
of labeled arginine in citrulline. Treatment of BAEC with
calcium ionophore A-23187 (105 M) in high-glucose environ-
ment caused a reduction of NOS activity of 70%, shifting the
conversion of L-(3H)-arginine to L-(3H)-citrulline from 24747
pmol/min per milligram of protein to 6557 pmol/min per
milligram of protein. These results further confirm that the effect
observed in high-glucose environment in stimulated conditions
is related to a reduction in eNOS activity rather than other
mechanisms such as NO quenching. Next, to further demon-
strate that the reduced NO release was caused by glucose effect
on eNOS, we used HEK293 stably transfected with eNOS. As
expected in these cells, the basal release of NO was higher and
it was significantly increased by treatment with A-23187. When
HEK293 were cultured in high-glucose environment, there was
a marked reduction in NO basal production as well as in the
stimulated condition (eg, A-23187-stimulated), thereby estab-
lishing that high-glucose environment negatively modulates
eNOS activity (Figure 5C).
Discussion
Szentivanyi and Pek first showed an altered vasodilatory re-
sponse in IDDM patients in the arterial bed of the conjunctiva in
1973.23 Since then, in several studies it has been demonstrated
that a substantial link between diabetes and vascular disorders
culminate in atherosclerosis, with the most common complica-
tion being diabetes.24–28 In the past 10 years, much attention has
been focused on a particular strain of mice whose diabetes
strongly resembles the human disease (the NOD mice).29 How-
ever, these mice have been used to study diabetes on elevation of
blood glucose over the physiological limit at different patholog-
ical values of glycemia or glycosuria and were selected for
specific different experimental protocols. Thus, most of the
results are not comparable, and studies on the linkage between
diabetes progression and vascular functionality on this particular
strain of mice are still lacking.
Figure 4. A, Disease progression does not affect eNOS expres-
sion. B, The disease progression significantly increases
caveolin-1 expression. Blots are representative of 3 separate
experiments. C, Densitometric analysis shows that there is a
significant increase in CAV-1 expression in NOD group 3 mice
only. *P0.05 versus CD-1, NOD groups 1 and 2.
Figure 5. A, In BAEC exposed to high-glucose environment, there
is a significant reduction of A-21387–induced NO release (n4;
P0.001). B, Reduction in NO release is coupled to an increased
caveolin-1 expression (n4; P0.01) with no changes in eNOS
expression (n4; NS). C, HEK-293 cells stably transfected with
eNOS in the basal (n4; P0.01) and the stimulated release of NO
(n4; P0.001) are significantly reduced in high-glucose environ-
ment. **P0.01 stimulated in high-glucose (H) versus stimulated in
normal glucose (N); ***P0.001 basal in H versus basal in N. The
results are expressed as meanSEM of 4 separate experiments
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Vascular tone is driven by a dynamic process in which several
signals that are either cell-mediated or receptor- mediated are
involved. A major role is played by vascular adrenoreceptors,
and this effect is coupled to the regulatory role played by the
endothelium through mediator release. This complex and finely
tuned interplay is disrupted by diabetes resulting in endothelial
dysfunction. Our study shows that NOD group 1 mice, with null
or low glycosuria, behave as normal outbred CD-1 mice. This
result implies that it is important to use NOD mice with
consistent glycosuria/glycemia to study angiopathy associated
with diabetes. Indeed, in NOD mice with high glycosuria (NOD
group 2 and group 3), an impaired vascular reactivity of the
adrenergic system was consistently observed. In particular, high
glycosuria (NOD group 2 mice) is associated with a reduction in
1 receptor expression, whereas a severe glycosuria (NOD group
3 mice) causes a complete ablation of the contractile response
associated with a further reduction of 1 receptor expression.
Similarly, the relaxing response to isoproterenol (2) is reduced
in high and severe glycosuria associated with a reduction in 2
receptor expression. PCR analysis performed on NOD group 3
mice aortas demonstrated that high glucose levels downregu-
lated both receptors at transcriptional level. This experimental
evidence finds a match with the human disease, in which it has
been shown that in non-complicated IDDM there is a chronic
decrease in sympathetic drive.30 In addition, it has been shown
that insulin infusion increases sympathetic activity,31 suggesting
that the lack of insulin in diabetes type 1 in humans is directly
related to a reduction of the adrenergic function. Thus, it appears
that diabetes progression is linked to a selective disruption of the
sympathetic drive. To evaluate if in this animal model there is
such selectivity, we have assessed if vascular reactivity impair-
ment in NOD mice is specific for adrenergic receptors by using
another 2 contracture agents, eg, 5-HT and DA. Aortic rings
from NOD group 3, in which there is a complete lack of
response to 1 stimulation, still contracted to 5-HT and DA,
further stressing that diabetic conditions caused a selective
impairment of the adrenergic function. It is also important to
note that NOD group 2, in which glycosuria ranges between 20
mg/dL and 500 mg/dL, displays the same impaired response to
adrenergic stimulation and reduced expression of 1 and 2
receptors.
Another important role in controlling vascular homeostasis is
played by eNOS-derived NO. Thus, we have investigated the
role of endothelium by measuring NO-dependent response in the
aortic rings. A significant reduction in Ach-induced vasorelax-
ation was observed in mice with severe glycosuria, whereas at all
the other levels of glycosuria the response to Ach was un-
changed. Aortas from NOD 1, 2, and 3 relaxed similarly with
exogenous NO. These results imply that L-arginine/NO pathway
is the last to be impaired by the progression of the disease; and
vessels, even at very high levels of glycosuria, still maintain at
least in part their ability to relax with endogenous agonist, eg,
Ach. It is known that vessels generate a tonic amount of NO that
is dynamically and constantly produced by eNOS and that
removal of this tonic activity by addition of an NO inhibitor
causes an increase in vascular tone in vitro and blood pressure in
vivo. When rings from NOD group 2 and 3 mice were
challenged with L-NAME, there was a marked and significant
reduction in the increase in tension indicating that in the
presence of high or severe glycosuria, an impairment of eNOS
activation/activity occurs. Thus, in this mouse strain reduction in
vascular adrenoreceptor expression is also coupled with a
reduction in formation of eNOS-derived NO. Also, this finding
fits with the demonstration that IDDM patients have an impair-
ment in NO release.32–34 Western blot analysis of aortas of NOD
groups and CD-1 demonstrated that there are no differences in
eNOS expression, indicating that the reduction of NO release in
diabetes is not linked to a reduced expression of the enzyme.
This finding is further corroborated by the cell studies performed
in high-glucose and normal glucose environments. Whereas in
BAEC grown in high glucose levels basal NO release is not
affected, a significant reduced production of NO in stimulated
condition (eg, calcium ionophore A23917) is present. The
finding that the high-glucose environment specifically modu-
lates eNOS activity is further confirmed by the reduced conver-
sion of labeled arginine in citrulline. In addition, in HEK 293
stably transfected with eNOS, there is a significant reduced
production of NO in basal and stimulated conditions in the
high-glucose environment. eNOS activity is regulated by dy-
namic subcellular targeting, regulatory protein–protein interac-
tions,35,36 and protein phosphorylation,37,38 many of which can
be modulated by stimuli in a calcium-dependent or calcium-
independent manner.35,36 In general, in the basal state, eNOS is
negatively regulated by several proteins, thus producing low
levels of NO. eNOS is located within the plasma membrane
microdomain caveolae, where it is complexed with the coat
protein for this organelle, termed CAV-1. CAV-1 is a 22-kDa
protein that decorates the cytoplasmic surface of caveolae and
serves as the primary structural component of caveolae (50 to
100 nm invaginations of the plasma membrane), where it acts as
a physiological inhibitor of eNOS.39,40 On activation of endo-
thelial cells by a cadre of mediators, the caveolin-1 inhibitory
clamp is diminished by the recruitment of several proteins that
promote an activation complex.41 For this reason, we have
evaluated whether diabetic conditions could modulate
caveolin-1 expression downregulating through this mechanism
of eNOS activity. Western blot analysis for caveolin-1 shows a
significant increase of caveolin-1 expression in NOD group 3
aortas only, and this is in agreement with the functional data in
which a significant reduction to Ach response has been found in
NOD group 3 only. Furthermore, a similar increase in caveolin-1
coupled with an increase in NO production is present in BAEC
cells in high-glucose environments. Thus, the reduction of NO
release in IDDM can be ascribed to a reduction in eNOS activity
through an enhanced expression of caveolin-1. This hypothesis
is corroborated by a study in which it has been shown that in
adipocyte plasma membrane, insulin receptor is localized in
caveolae,41 the same microdomain where eNOS resides.42 In
addition, it has been shown that caveolin-1, through its scaffold-
ing domain, potently stimulated insulin receptor kinase activity,
stabilizing the activated conformation of the regulatory region of
the receptor in an activated state.43 Thus, it is feasible that
IDDM, in which a progressive reduction of insulin production
occurs, there is an increase of caveolin-1 expression that leads
eNOS activity inhibition that in turn reduces NO production and
promotes and stabilizes insulin receptor in its active conforma-
tion. This latter finding could be interpreted as a body-adaptive
response to a reduction in insulin production, in which insulin
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receptor is more receptive to a minor concentration of insulin
because of IDDM.
In conclusion, on progression of diabetes in NOD mice, there
is a marked selective reduction in the adrenergic response
associated with a reduction in the expression of 1 and 2
receptors on vessels. When glycosuria is severe (eg, NOD group
3), a reduction in NO-dependent vasorelaxation occurs and this
is coupled with an enhanced caveolin-1 expression. Our results
indicate that studies on cardiovascular complications in diabetes
performed using NOD mice should be performed while account-
ing for disease progression in mice. In addition, our results
suggest that caveolin-1 may represent a new possible therapeutic
target in diabetes.
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Methods 
Reagents 
L-phenylephrine (PE), serotonin (5-HT), dopamine (DA), acetylcholine (Ach), isoproterenol (Isop), 
sodium nitroprusside (SNP), Nω-nitro-L-arginine methyl ester (L-NAME) were purchased from 
Sigma Chemical Co. (Milano-Italy). All salts used for Krebs solution preparation were purchased 
from Carlo Erba Reagenti (Milan, Italy). Anti-α1, anti-β2 and anti-caveolin-1 IgG were purchased 
from Santa Cruz Biothechnology Inc (Santa Cruz, California, USA). Anti-eNOS was purchased 
from Transduction Laboratories (BD Biosciences). All salts used for western blot analysis were 
purchased from ICN Biochemical (Eschwege, Germany).  
Animals 
Female Non Obese Diabetic mice (NOD/Ltj) and CD-1 mice, were purchased from Charles River 
(Italy). NOD mice exhibit a susceptibility to spontaneous development of autoimmune (type I) 
insulin dependent diabetes mellitus (IDDM)1. Diabetes development in NOD mice is characterised 
by insulitis and leukocytic infiltrate of the pancreatic islets. Progressive reduction in pancreatic 
insulin content starts at about 12-16 weeks of age. 
Measurement of glycosuria  
To assess the diabetic condition of NOD animals, glycosuria was evaluated weekly to select 
the animals. This method was used since it is non invasive and it well correlates with an increase in 
blood glucose. Groups of 3 mice were placed in metabolic cages able to selectively collect urine, for 
at least 4h. The content of glucose in the urine was measured by using Trinder reaction2 (Glucose 
Trinder 100, Sigma Chemical Co. Milano, Italy). This method is based on the glucose oxidation to 
gluconic acid and hydrogen peroxide in the reaction catalysed by glucose oxidase. Briefly, the 
hydrogen peroxide formed reacts in the presence of peroxidase with 4-aminoantipyrine and p-
hydroxybenzene sulfonate to form a quinoneimine dye, with maximum absorbance at 505 nm. The 
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value of absorbance is directly proportional to the glucose concentration in the sample. The value of 
glycosuria (gl) obtained is correlated to the age of the animals (Figure 1), therefore mice have been 
divided in the following groups:  
• NOD group I  0<   gl   <5 mg/dl   = low o null glycosuria 
• NOD group II  20<  gl   <500 mg/dl   = high glycosuria 
• NOD group III  500 < gl to 1000 mg/dl = severe glycosuria 
 
Animals were sacrificed at these different points and aortas were dissected and used for western 
blotting analysis or for tissue bath experiments. Experiments were performed also on CD-1 mice in 
order to have an internal non diabetic control to compare with NOD I 
Tissue preparation 
NOD or CD-1 mice were sacrificed and thoracic aorta was rapidly dissected and cleaned from fat 
and connective tissue. Rings of 1.5-2 mm length were cut and mounted on wire myographs (Kent 
Instruments, Japan) filled with gassed Krebs solution (95% O2+ 5% CO2) at 37°C. Changes in 
isometric tension were recorded with PowerLab data acquisition system (Ugo Basile, Italy).The 
composition of the Krebs solution was as follows (mol/l): NaCl 0.118, KCl 0.0047, MgCl2 0.0012, 
KH2PO4 0.0012, CaCl2 0.0025, NaHCO3 0.025 and glucose 0.010. Rings were initially stretched 
until a resting tension of 1.5 g was reached and allowed to equilibrate for at least 40 minutes during 
which tension was adjusted, when necessary, to 1.5 g and bathing solution was periodically 
changed. In a preliminary study a resting tension of 1.5 g was found to develop the optimal tension 
to stimulation with contracting agents.  
 
Experimental protocols 
In each experiment rings were firstly challenged with PE (1 µM) until the responses were 
reproducible. To evaluate tissue contractility, cumulative concentration response curve to PE (10 
nM-30 µM), 5-HT (10 nM-30 µM) and DA (10 nM-30 µM) were performed. Conversely, to 
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evaluate tissue vasorelaxation, cumulative concentration response curve to Ach (10 nM-30 µM), 
SNP (1 nM-3 µM) and Isop (10 nM-30 µM) were performed on PE-precontracted rings. In addition, 
Ach cumulative concentration response curve was performed also in 5-HT-precontracted rings. In a 
separate set of experiments rings were contracted with 5-HT 300 nM, once plateau was reached L-
NAME 100 µM was added. 
 
Western Blotting 
Aortic tissue samples were homogenised in lysis buffer (β-glycerophosphate 0.5 M, sodium 
orthovanadate 10mM, MgCl2 20mM, EGTA 10mM, DTT 100mM and protease inhibitors) using a 
Talon homogenizer, and were processed identically. Protein concentration was determined using 
Bradford assay (Bio-Rad Laboratories, Segrate, MI). Proteins (30 µg) were subjected to 
electrophoresis on an SDS 10% polyacrylamide gel and electrophoretically transferred onto a 
nitrocellulose transfer membrane (Protran, Schleicher & Schuell, Germany). The immunoblots were 
developed with 1:500 dilutions  for α1 and β2 receptors and 1:1000 for eNOS and caveolin-1, and 
the signal was detected with the ECL System according to the manufacturer’s instructions 
(Amersham Pharmacia Biotech).   
 
RT-PCR analysis 
 
CD-1 and NOD mice were sacrificed and thoracic aorta was dissected and immediately snap frozen 
on liquid nitrogen. Total RNA was prepared using RNeasy Fibrous Tissue  Kit (Qiagen) according 
to the manufacturer’s instructions. Traces of genomic DNA that may copurify with RNA are 
removed by a DNase treatment on the same spin column provided with the kit. Total RNA was 
reverse-transcribed using random hexamers, as described. One-tenth of each cDNA sample was 
amplified by PCR with α1 and  β2  adrenergic receptor-specific primers. Each sample contained the 
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sense and antisense primers 1µM, 200 µM dNTPs, 50 mM KCl, 20 mM Tris- HCl, pH 8.6, 1.5 mM 
MgCl2 ,,and 1.25 U Platinum Taq Polymerase (Invitrogen). Thermal cycling was performed for  30 
seconds at 94 °C, 30 seconds at 55°C and 45 seconds at 72°C After 24, 26 28 30 and 32 cycles 30 
seconds pause were programmed to obtain 5 µl sample. The sense and antisense primers (5’→3’) 
were AGGCTGCTCAAGTTTTCCCG and GCTTGGAAGACTGCCTTCTG for α1a adrenergic 
receptor (283 bp), and GCCATCCTCATGTCGGTTAT and AGCAGGCTCTGGTACTTGAA for 
β2 adrenergic receptor (326 bp).For mouse β-actin the primers pair used were 
’TGTGATGGTGGGAATGGGTCAG3’ for the sense and 5’TTTGATGTCACGCACGATTTCC 
3’ for the antisense sequence (514 bp). PCR was carried out for 30 cycles as follow: 45 seconds at 
94 °C, 45 seconds at 60°C and 1 minute at 72°C (514 bp).Control PCR reactions also were 
performed on non- reverse transcribed RNA to exclude any contamination by genomic DNA. The 
amplified DNAs were analysed on a 1.8 % agarose gel, the fragment size  was assesed by 
comparison  with 100bp DNA marker (Invitrogen). The gel was photographed under ultraviolet 
transillumination with a Kodak Digital Science ID Image Analysis Software, images were the 
digitalised and a semi-quantitative analysis was performed using the same software.  
 
Cell experiments with normal and  high glucose environment 
Human embryonic kidney (HEK-293) cells stable transfected with eNOS were gently provided by 
W.C. Sessa3. Bovine aortic endothelial cells BAEC cells were obtained by Istituto Nazionale per lo 
Studio e la Cura dei Tumori (Milano, Italy). The cells were cultured in 60mm Petri plastic dishes 
(FALCON, Microtech Italy) and grown in medium (GIBCO, Invitrogen Corporation) supplemented 
with 2mmol/l glutamine (GIBCO), 10% heat inactivated fetal calf serum (GIBCO), 50U/ml 
penicillin, 50U/ml streptomycin. The Petri dishes were incubated at 37°C in a 5%CO2-95% air gas 
mixture. BAEC were subcultured on reaching confluence by use of 0.01% trypsin-EDTA. The cells 
were used between passage 5 and 6. Cells were grown until they reached 90% confluence and then 
were serum starved overnight. 
 5
BAEC were pre-treated for 3h with 11.5mM D-glucose solution (normal glucose) or 25mM D-
glucose solution e. g. high glucose4 and eNOS activation by the known agonist the calcium 
ionophore A23187 (10-5M, 30min)4 was examined. The medium was collected and nitrite were 
assayed fluorometrically in microtiter plates using a standard curve of sodium nitrite. The same 
protocol was utilised for HEK-293 reducing the time of incubation with high glucose to 2h. 
Preliminary experiments showed that high glucose induced apoptosis in Hek-293 cells after 3h.  
 
eNOS activity 
 
Activity was determined as described previously5 BAEC were incubated for 60 min with L- (3H)-
arginine 185 x 103 (5µCi). Cells were washed twice with PBS in order to remove the L- (3H)-
arginine in excess. BAEC were then treated for 3h with 11.5mM D-glucose solution (normal 
glucose) or 25mM D-glucose solution and then  calcium ionophore A23187 (10-5M)  added as 
described above. After 30 min of incubation 2ml of cold PBS containing 5mmol/L L-arginine and 
4mmol/L EDTA were added to stop the reaction. Ethanol (0.4ml), 95%) was then added and after 
evaporation 2 ml of 20mmol/L Hepes –NA (pH 6) were added. The supernatants were collected, 
applied to 2 ml columns of Dowex AGWX8-200 (Aldrich, Milano, Italy) to trap radioactive 
arginine and eluted by 4ml of  water  to elute radioactive citrulline. Eluted radioactivity was  
measured by liquid scintillation counting. 
 
Statistical Analysis 
All data were expressed as mean±SEM. Statistical analysis was performed by using 2-way ANOVA  
and paired and unpaired Student t-test where appropriate. Differences were considered statistically 
significant when P value was less than 0.05. 
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